Shi Xiaoyu, Zhang Kun, Yu Fengshi, Qi Qi, Cai Xiaoyu, Zhang Yu
State Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
VCANBIO Cell and Gene Engineering Corp. Ltd., Tianjin, China.
Stem Cells Int. 2024 Sep 30;2024:4073485. doi: 10.1155/2024/4073485. eCollection 2024.
The effectiveness and safety of mesenchymal stem cell (MSC) therapy have been substantiated across various diseases. Nevertheless, challenges such as the restricted expansion capacity of tissue-derived MSCs and the clinical instability due to the high heterogeneity of isolated cells require urgent resolution. The induced pluripotent stem cell-derived MSCs (iPSC-MSCs), which is differentiated from iPSCs via specific experimental pathways, holds considerable potential as a substitute for tissue derived MSCs. Multiple studies have demonstrated that iPSCs can be differentiated into iPSC-MSCs through diverse differentiation strategies. Research suggests that iPSC-MSCs, when compared to tissue derived MSCs, exhibit superior characteristics in terms of proliferation ability, immune modulation capacity, and biological efficiency. In this review, we meticulously described and summarized the experimental methods of iPSC differentiation into iPSC-MSCs, the application of iPSC-MSCs in various disease models, the latest advancements in clinically relevant iPSC-derived cell products, and the development strategies for the next generation of iPSC-derived therapy products (not only cell products but also their derivatives).
间充质干细胞（MSC）疗法的有效性和安全性已在多种疾病中得到证实。然而，诸如组织来源的间充质干细胞扩增能力受限以及由于分离细胞高度异质性导致的临床不稳定性等挑战亟待解决。通过特定实验途径从诱导多能干细胞（iPSC）分化而来的诱导多能干细胞来源的间充质干细胞（iPSC-MSC），作为组织来源间充质干细胞的替代品具有巨大潜力。多项研究表明，iPSC可通过多种分化策略分化为iPSC-MSC。研究表明，与组织来源的间充质干细胞相比，iPSC-MSC在增殖能力、免疫调节能力和生物学效率方面表现出更优异的特性。在本综述中，我们精心描述并总结了iPSC分化为iPSC-MSC的实验方法、iPSC-MSC在各种疾病模型中的应用、临床相关的iPSC来源细胞产品的最新进展以及下一代iPSC来源治疗产品（不仅是细胞产品，还包括其衍生物）的开发策略。
